Cross-Sector entity

FDA

Company
5.6

CDC is the most frequent co-covered peer, appearing in 3 of the 5 tracked stories. regulation accounts for 2 of the 5 tracked stories, while 3 other categories carry the remainder. Each carries 2 original sources on average. Negative sentiment appears in 60% of the tracked stories.

5 verified stories tracked

Last mentioned: 4d ago

Entity pulse

Recent coverage · FDA

5 stories
5.6 avg impact
0% positive
60% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 60 percentage points.

  • 40% neutral
  • 60% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about FDA

CDC is the most frequent co-covered peer, appearing in 3 of the 5 tracked stories. regulation accounts for 2 of the 5 tracked stories, while 3 other categories carry the remainder. Each carries 2 original sources on average. Negative sentiment appears in 60% of the tracked stories. This profile follows 5 Cross-Sector stories mentioning FDA across the period from September 7, 2026 to September 8, 2026.

Stories tracked
5
Negative
60%
Sources per story
2

Computed from the 5 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering FDA. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Coverage Highlights Market Divergence

    Financial media report on the stock's surge and note some Wall Street price targets are more upbeat than Cramer's caution.

  2. Cramer Calls NUVB 'Pure Speculation'

    On CNBC's Mad Money, Jim Cramer warns Nuvation Bio trades on what pipeline drugs might do someday rather than steady revenue.

  3. FDA Grants Fast Track Designation to Safusidenib

    Nuvation Bio's experimental brain cancer drug safusidenib receives FDA Fast Track status for IDH1-mutant glioma.

  4. Nationwide Cyclospora outbreak tied to contaminated lettuce

    An ongoing nationwide Cyclospora outbreak is linked to contaminated lettuce and a Mexican farm, drawing attention to the declining FDA foreign inspection capacity.

  5. Pandemic-driven inspector attrition begins

    The COVID-19 pandemic kicks off a wave of retirements and departures among FDA inspectors that continues to this day.

  6. Pre-pandemic baseline for FDA foreign inspections

    FDA foreign food site inspections are recorded at a baseline level before the COVID-19 pandemic; subsequent records reviewed by AP show inspections have fallen nearly 35% since this year.

Stories mentioning FDA 5

Finance markets Neutral 5

Cramer's 5-Word NUVB Warning as Biotech Surges: 2026 Net Loss Expected

Jim Cramer's September 3 'pure speculation' call on Nuvation Bio hits at a moment of momentum: shares rose on FDA Fast Track news and strong early IBTROZI adoption. Yet analysts forecast a full-year 2026 net loss, making the rally a contest between pipeline optionality and burn rate.

2 sources